Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
about
Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of SubgroupsDouble or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallelChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewStroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsDabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional ExperienceAtrial fibrillation: a review of recent studies with a focus on those from the duke clinical research instituteChoosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to KnowNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsCardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome.Atrial fibrillation as a prognostic indicator of myocardial infarction and cardiovascular death: a systematic review and meta-analysisTrials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?Approach to the new oral anticoagulants in family practice: part 1: comparing the options.Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.Selecting antithrombotic therapy for patients with atrial fibrillation.Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic AttackDabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixabanInflammation and hemostasis in atrial fibrillation and coronary heart disease: The REasons for Geographic And Racial Differences in Stroke study.Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran.National Trends in Ambulatory Oral Anticoagulant Use.Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.Anticoagulation in Atrial FibrillationAnticoagulation in Atrial Fibrillation - Current ConceptsNovel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patientThe clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patientsRelevance of stroke subtype in vascular risk prediction.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation.Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial FiPharmacological Therapy in Stroke Prophylaxis - The New versus the Old AgentsPrevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation
P2860
Q21284803-9816F8E4-14EE-42D2-A7C8-288034D48A8EQ26741058-14F0263A-F213-4C57-8E73-919996CE2CCAQ26765949-AFF0F443-5803-4BDB-AFEE-B9DD4D319C80Q26781181-19EECD9E-E7FB-4636-9EDC-B1E666D0B637Q26783457-E553A27C-2A7A-4A1D-83E7-572C5ABC04CFQ26851235-87B369C7-E962-488C-93ED-0E1B85123D9EQ28074445-63601686-0895-461B-A91A-DBC70B6C3AE1Q28080616-39745E18-21B5-4D7D-8159-63867B47D5DCQ30680968-92CDFECF-D40F-4ACA-9EC9-6976798542CFQ33403263-8B491D67-4FCB-496D-8459-E3FFBF050F8DQ33794241-97238B9E-092D-446F-A77B-3B65C7FBF7C0Q33911981-5EE9DEB6-5F4E-4BA5-8F0D-C9A7D720274EQ34099930-B5E8BD0F-17D2-47DD-BD7D-212A351EAE84Q34109813-DF53AC28-8405-4E60-B4A5-921D4E3570D7Q34223524-B948416F-F6CE-46A3-8E94-7AF6E467438CQ34497581-192DC293-0F41-4559-8BF6-828F5DB4A7C7Q34650638-9203A824-A5C6-4383-BD1C-83CBD6890A91Q34651051-F63B8685-24C6-4E12-8E2B-AFFBCE5CF7F5Q35062047-6E93DFD1-1BBB-45F4-BF9F-B02838C0E2C6Q35542784-DCC9DB32-7B0B-45B6-99FF-779CAF6A332DQ35650380-A974F322-D7E0-4DBF-8DD6-894F81A7F677Q35851558-5FB4EFB8-DE6B-4E13-8B08-D38430EC4171Q35883245-062172D0-1D63-4282-BFC4-F84CD1ED3EBFQ35975334-F2181E74-BF9D-49C4-8620-2029A21B388BQ36241389-DAE5CAEC-CCC9-4AAF-B24B-B0199FE9C46FQ36253510-86794B9C-BA2C-407B-820F-9721A0584936Q36283736-03981191-6845-471A-9B5E-7EDDFE3F29D3Q36315659-DB9FDED3-A0F8-421D-B53B-2F92684E39ADQ36370296-2AF6E25A-2BAD-42BB-9089-EF395FFD7E63Q36372800-1E6E4F8B-51C2-483C-B3C6-E145051FB46DQ36458782-A522857F-101D-4994-8691-B87A990B6BCAQ36458853-885EF22C-81BC-4A0B-A841-B992D17159F5Q36723401-70F43CAF-12D4-492E-98FD-90A1353E2D71Q37014482-FC099522-E59C-41F8-BD74-474B85EEAA69Q37178743-76DD8BB0-B3AA-4388-BB9F-CA0B9730EC4AQ37251490-2F7D402D-B48D-4846-B190-9E4DACFAC2DEQ37382897-4E8B64C7-ED6E-4792-8FB6-E26FF01F017DQ37412869-09F85E49-66E7-4F11-8AA2-03A5E4F08C87Q37495788-27CFFE7C-201B-4E7D-AD8C-CB4A78876624Q37495942-42F54769-4392-4481-9B6E-07741947E309
P2860
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Myocardial ischemic events in ...... nticoagulation Therapy) trial.
@en
Myocardial ischemic events in ...... atran or warfarin in the RE-LY
@nl
type
label
Myocardial ischemic events in ...... nticoagulation Therapy) trial.
@en
Myocardial ischemic events in ...... atran or warfarin in the RE-LY
@nl
prefLabel
Myocardial ischemic events in ...... nticoagulation Therapy) trial.
@en
Myocardial ischemic events in ...... atran or warfarin in the RE-LY
@nl
P2093
P50
P921
P1433
P1476
Myocardial ischemic events in ...... nticoagulation Therapy) trial.
@en
P2093
Jonas Oldgren
Martina Brueckmann
Michael Ezekowitz
Paul Reilly
Stefan H Hohnloser
Stuart J Connolly
P304
P356
10.1161/CIRCULATIONAHA.111.055970
P407
P577
2012-01-03T00:00:00Z